IRCT20210622051666N1
Recruiting
Phase 3
Evaluation of oral N-acetylcysteine efficacy versus placebo in prevention of mucositis induced by radiotherapy and chemotherapy agents in children with malignancy A double blind randomized clinical trial
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ahvaz University of Medical Sciences
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who are 2\-18 years old
- •Recipients of radiotherapy and anti\-metabolite chemotherapy drugs with a high risk of developing oral mucositis (including Doxorubicin, Methotrexate, FU Etoposide, Cytarabine and Melphalan) and other drugs listed below.
- •Patients with lansky performance scale index above 70%
- •No Cardiovascular disease
Exclusion Criteria
- •Causes any severe allergic reactions to the drug (such as skin complications, bronchospasm, bronchitis, etc.)
- •Any active gastrointestinal disease
- •Cardiovascular disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Oral N-acetylcysteine (NAC) effectiveness in cystic fibrosis (CF)IRCT20090808002306N7Esfahan University of Medical Sciences45
Not yet recruiting
Not Applicable
Efficacy of the oral use of the drug N-acetylcysteine in the treatment of facial melasma in womeMelasmaRBR-73zrnjhFaculdade de Medicina de Botucatu (FMB - Unesp)
Completed
Phase 3
acetylcysteine in the treatment of diarrhea caused by rotavirusDiarrhea caused by rotavirus.Rotaviral enteritisA08.0IRCT20181208041882N13Yazd University of Medical Sciences64
Recruiting
Phase 3
evaluation of N-acetylcysteine on nitrosative stress in Rheumatoid arthritis patientsIRCT2017073022965N12Vice Chancellor for research of Hamadan University of Medical Sciences52
Completed
Phase 4
To determine efficacy of oral N-Acetyl Cysteine in patients with Chronic Obstructive Pulmonary Disease (COPD)Health Condition 1: null- Chronic Obstructive Pulmonary Disease (COPD)CTRI/2011/09/001988Cipla Ltd40